# US 11,897,902 B1 · Nano-sized mixed ligand [4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine- phenanthroline] Ru(III) complex for medicinal applications > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,897,902 B1 - Document ID: US11897902B1 - Status: Granted - Kind: B1 - Application number: 18/372,657 - Filed: 2023-09-25 - Granted: 2024-02-13 - Earliest claimed: 2023-09-25 - Assignees: King Faisal University - Applicants: King Faisal University - Inventors: Hany Mohamed Abd El-Latef Ahmed; Mai Mostafa Khalaf Ali; Tarek El-Dabea; Seraj Alzahrani; Ahmed M. Abu-Dief - Web page: https://patentgrep.com/patent/US11897902B1 ## CPC - C07F 15/0053: {without a metal-carbon linkage} - A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)} - A61K 47/547: {Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent} - A61P 31/04: Antibacterial agents - A61P 31/10: Antimycotics - A61P 35/00: Antineoplastic agents - B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery - B82Y 40/00: Manufacture or treatment of nanostructures - C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES ## Abstract A compound 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex, its synthesis, and its use for pharmaceutical applications. ## Claims ### Claim 1 A 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex having the formula I: ### Claim 2 (depends on 1) The 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex of claim 1, wherein the complex is formed as nanoparticles. ### Claim 3 (depends on 2) The 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex of claim 2, wherein the nanoparticles have a semi-spherical shape. ### Claim 4 (depends on 2) The 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex of claim 2, wherein the nanoparticles have an average size of about 25 nm to 30 nm. ### Claim 5 (depends on 2) The 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex of claim 2, wherein the nanoparticles have an average particle size of about 28 nm. ### Claim 6 (depends on 1) A pharmaceutically acceptable composition comprising a therapeutically effective amount of the 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex of claim 1 and a pharmaceutically acceptable carrier. ### Claim 7 (depends on 1) A method of treating a microbial infection in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex of claim 1. ### Claim 8 (depends on 7) The method of claim 7, wherein the microbial infection is caused by one or more of Escherichia coli and Aspergillus flavus. ### Claim 9 (depends on 1) A method of treating cancer in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex of claim 1. ### Claim 10 (depends on 9) The method of treating cancer of claim 9, wherein the cancer is breast cancer. ### Claim 11 (depends on 1) A method of promoting an antioxidant effect in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of the 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex of claim 1. ### Claim 12 (depends on 1) A method of making the 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex of claim 1, the method comprising: adding a solution of Ruthenium (III) chloride (RuCl3) in ethanol to a 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine ligand in ethanol ethanol to obtain a first mixture; sonicating the first mixture; adding phenanthroline to the first mixture to obtain a second mixture; sonicating the second mixture; and obtaining the 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex. ### Claim 13 (depends on 12) The method of making the 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex of claim 12, wherein the RuCl3 is added stepwise. ### Claim 14 (depends on 12) The method of making the 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex of claim 12, wherein the first mixture is sonicated for at least 30 minutes. ### Claim 15 (depends on 12) The method of making the 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex of claim 12, wherein the second mixture is sonicated for at least 30 minutes. ### Claim 16 (depends on 12) The method of making the 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex of claim 12, wherein the RuCl3 and the phenanthroline are mixed in an about 1:1 molar ratio. ### Claim 17 (depends on 12) The method of making the 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex of claim 12, wherein the 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex is a dark brown crystalline powder. ### Claim 18 (depends on 12) The method of making the 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex of claim 12, wherein the 4-bromo-2-(quinolin-2-yliminomethyl)-phenol imine]-Ru(III)-phenanthroline complex is a nanosized complex.